Lilly’s Omvoh leads to 50% clinical remission rate in paediatric UC

Data ReadoutpositiveOmvohPositive

AI Analysis

Summary

Lilly reported that Omvoh produced a 50% clinical remission rate in paediatric ulcerative colitis. The company said it will supply the data to the FDA to support a label expansion.

Clinical Trial Data

Outcome Details

50% clinical remission rate in paediatric ulcerative colitis; Lilly plans to supply data to the FDA to support label expansion.

Importance:5/10

Sentiment:

0.60

ulcerative colitispaediatriclabel expansionIL-23FDA submissionclinical remission

Related Companies

$LLY

Read the original article

Published by Clinical Trials Arena on October 19, 2026 10:50 AM

Read Original